Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study

BACKGROUND: FOLFOXIRI is now regarded as the chemotherapy regimen that offers the best platform for the treatment of colorectal cancer. However, the safety and efficacy of FOLFOXIRI + panitumumab has not been demonstrated. We conducted a phase I study to determine the recommended dose of FOLFOXIRI +...

Descripción completa

Detalles Bibliográficos
Autores principales: Satake, Hironaga, Tsuji, Akihito, Nakamura, Masato, Ogawa, Masaaki, Kotake, Takeshi, Hatachi, Yukimasa, Yasui, Hisateru, Takagane, Akinori, Okita, Yoshihiro, Nakamura, Kumi, Onikubo, Toshihide, Takeuchi, Masahiro, Fujii, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951897/
https://www.ncbi.nlm.nih.gov/pubmed/29464396
http://dx.doi.org/10.1007/s10147-017-1228-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951897/
https://www.ncbi.nlm.nih.gov/pubmed/29464396
http://dx.doi.org/10.1007/s10147-017-1228-5

Ejemplares similares